Global Drug Delivery Devices Market

The analgesics market consists of sales of analgesic drugs and related services. Analgesics also known as pain killers are used to treat mild or severe pain, including musculoskeletal pain, surgical, trauma pain, cancer pain or other type of pains. Examples of analgesics includes codeine, hydrocodone, oxycodone and methadone The different types of analgesics are non-opioids and opioids. Non-opioid analgesics are pain relievers available over-the-counter (OTC) and by prescription. They are rapidly being promoted as a desirable, safe, and productive first-line therapeutic alternative to opioid drugs in a range of clinical settings for mild to severe acute and chronic pain. The different types of drugs include prescription analgesics, OTC analgesics and involves various routes of administration such as oral, intravenous, rectal, transdermal, topical. It is used in internal analgesics, external analgesics and distributed through various channels such as hospital pharmacies, retail pharmacies, drug stores. The global analgesics market size is expected to grow from $104.72 billion in 2021 to $110.08 billion in 2022 at a compound annual growth rate (CAGR) of 5.1%. The change in the analgesics market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The market is expected to reach $127.15 billion in 2026 at a CAGR of 3.7%. Significant rise in prevalence of chronic diseases is driving the analgesics Market. Analgesic drugs, also known as painkillers, are used to treat and reduce chronic or severe pain in the body resulting from various medical conditions. According U.S. Centers for Disease Control and Prevention National Center for Health Statistics briefing published in 2019, around 20% of the USA population suffer from chronic pain in the USA. Also, there has been an increase in prevalence of diseases like cancer which increases the number of people suffering from chronic pain. The growth of analgesics market is restricted by the increasing use of biologics for the treatment of inflammatory and neuropathic pain. Biologics are drugs produced from living organisms and include a number of components derived from human, animals or microorganisms. These drugs may contain protein, modified human hormones, or cells that produce substances that suppress or activate parts of the immune system. Biologics can provide greater efficacy compared to analgesics, which provide effective pain relief to only 50% of the patients, and is thus widely used nowadays. Rising demand for biologics can adversely impact the growth of the Analgesics market. For instance, Pfizer and Lilly were granted approval by the FDA for developing Tanezumab, a biologics medicine. Companies in the analgesics market are increasingly focusing on acquisition as a strategy for growth. Leading analgesic drug manufacturers are acquiring smaller companies to gain competitive advantage and strengthen their market position. These acquisitions are helping companies to expand geographically and gain specialized expertise in research and development of new products. For instance, Analgesic Solutions, LLC was acquired by WCG in the 2019. WCG intends to make use of superior R&D capability of Analgesic Solutions, LLC to grow and position itself as a market leader in the Analgesic Market. The US Food and Drug Administration (FDA) and the UK's Medicines and Healthcare products Regulatory Agency are some of the regulatory bodies that regulate the Analgesic Market. For instance, FDA has provided guidelines on manufacturing process of analgesics, and safety measures regarding use of both opioid and non- opioid analgesics. FDA also regulates and monitors misuse and abuse of opioid analgesics. Opioid analgesics are prohibited to be sold without proper medical prescription. Similarly, the Medicines and Healthcare products Regulatory Agency in the UK safeguards the public interest through effective regulation of analgesics drugs. In April 2019, WCG, a US-based pharmaceuticals company acquired Analgesic Solutions, LLC for an undisclosed amount. WCG's newest acquisition aims to improve test sensitivity in clinical trials, through advising, novel tools, data science, technology, and specialised training. Analgesic Solutions, LLC is a US based pharmaceutical company that specializes in the development of new pain medications. Major players in the analgesics market are Bayer Healthcare, Pfizer, Sanofi, Johnson & Johnson, Novartis AG, GlaxoSmithKline PLC, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb and Eli Lilly and Company. North America is the largest region in the analgesics market in 2021. The Middle East is expected to be the fastest growing region in the global analgesics market during the forecast period. The regions covered in the global analgesics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the analgesics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global analgesics market is segmented - 1) By Type: Non-Opioids, Opioids 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores 3) By Route of Administration: Oral, Intravenous, Rectal, Transdermal, Topical 4) By Drug Type: Prescription Analgesics, OTC Analgesics 5) By Application: Internal Analgesics, External Analgesics

The implantable drug delivery devices market consists of sales of implantable drug delivery devices and related services by companies that manufacture them. Implantable drug delivery devices are drug delivery systems implanted by surgery to allow site-specific drug administration at the tissue or organ where the drug is most needed. The main product of implantable drug delivery devices is contraceptive implants, spinal implants, brachytherapy seeds, drug-eluting stents, bioabsorbable stents, intraocular stents, infusion pumps, and others. Spinal implants are devices that are used by surgeons while performing surgery to treat deformity, stabilize and strengthen the spine, and facilitate fusion. The technologies involved are diffusion, osmotic, magnetic, and others. The various applications involved are contraception, ophthalmology, cardiovascular, diabetes, oncology, autoimmune diseases, and others. The global implantable drug delivery devices market size is expected to grow from $17.20 billion in 2021 to $18.35 billion in 2022 at a compound annual growth rate (CAGR) of 6.7%. The global implantable drug delivery market is then expected to grow to $24.08 billion in 2026 at a CAGR of 7.0%. The rise in the incidence of target diseases such as diabetic retinopathy, cancer, cardiovascular diseases, and other chronic diseases is expected to drive the implantable drug delivery devices market. According to the International Diabetes Federation (IDF), the global prevalence of diabetic retinopathy was around 27% in 2019. Implantable drug delivery devices are used for site-specific drug administration where the drug is most needed, such as Gliadel® wafer as an implant used in the treatment of brain tumors, Lupron depot for the treatment of prostate cancer. Hence, the site-specific drug administration nature of implantable drug devices, which help in the treatment of target diseases, is driving the implantable drug delivery devices market. The rising number of product recalls and lawsuits associated with implantable drug delivery devices is expected to hinder the market. In the past few years, there had been an increase in product recalls and lawsuits connected with these devices. For instance, in December 2019, around 7,000 Medtronic SynchroMed II, implantable drug infusion pumps were recalled due to the presence of foreign bodies in them. Nexplanon, a small rod contraceptive implant inserted into the skin of the upper arm to prevent pregnancy for up to three years, is facing a lawsuit, and lawyers and attorneys at National Injury Help have been investigating all such cases against those injured by Nexplanon. Therefore, the rising number of product recalls and lawsuits concerning implantable drug delivery devices is expected to hinder the growth of the market. Companies and researchers are focusing on developing 3D implantable drug delivery devices. 3D printed titanium transcutaneous ports are implanted behind the patient's ear, allowing healthcare professionals to access the catheters. For instance, in February 2020, Renishaw and Herantis Pharma announced the award-winning device, which received positive results in phase 2 trials, that consists of up to four catheters implanted in the relevant brain areas. Researchers at King Abdullah University of Science and Technology have introduced a miniaturized drug delivery system suitable for in-vivo biomedical applications. The system consists of an electrolytic pump, which operates a micro bellows membrane as an actuator for delivery through microneedles. A two-photon 3D printing technique was used to make a reservoir equipped with a microneedle. In November 2019, Dare Bioscience, a USA-based biopharmaceutical company with a special focus on women's health, has acquired Microchips Biotech for an amount of $102 million. Through this acquisition, Microchips has become the wholly subsidiary of Dare Bioscience. Microchips Biotech is a USA-based company developing innovative drug implants. Major players in the implantable drug delivery devices market are Allergan Inc, Bayer HealthCare, Medtronic Inc, Nucletron, Boston Scientific Corporation, Abbott Laboratories, Bausch and Lomb Inc, Merck, Genetech Inc, and Psivida. North America was the largest region in the implantable drug delivery devices market in 2021. Asia Pacific was the second-largest region in the global implantable drug delivery device market during the forecast period. The regions covered in the global implantable drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global implantable drug delivery devices market is segmented - 1) By Product: Contraceptive Implants, Spinal Implants, Brachytherapy Seeds, Drug-Eluting Stents, Bio-Absorbable Stents, Intraocular Stents, Infusion Pumps, Others 2) By Technology: Diffusion, Osmotic, Magnetic, Others 3) By Application: Contraception, Ophthalmology, Cardiovascular, Diabetes, Oncology, Autoimmune Diseases, Others

The implantable infusion pumps market consists of sales of implantable infusion pumps and related services by entities (organizations, sole traders, and partnerships) that manufacture implantable infusion pumps. An implantable infusion pump is a small device that is put beneath the skin during the operation. The pump delivers the liquid pain medication to a different part of the body through a long, flexible tube called the catheter. The implantable infusion pumps market is segmented by type into patient-controlled analgesia (PCA) pumps, enteral pumps, insulin pumps, elastomeric pumps, syringe pumps, and others. The insulin pump is a small device that is put beneath the skin during the operation to deliver insulin in diabetic patients. The various applications of implantable infusion pumps are oncology, pediatrics/neonatology, gastroenterology, hematology, diabetes, and others that are used by hospitals, ambulatory surgical centers, and specialty clinics. The global implantable infusion pumps market size is expected to grow from $17.42 billion in 2021 to $18.26 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The global implantable infusion pump market is expected to grow to $21.79 billion in 2026 at a CAGR of 4.5%. The increased prevalence of people with chronic pain, cancer, and diabetes is expected to drive the demand for implantable infusion pumps, as these pumps are commonly used to deliver pharmaceutical drugs during the treatment of these diseases. Chronic illnesses and disorders are on the rise around the world, as the aging population and shifts in social behavior lead to a gradual increase in these diseases. In diseases such as chronic arachnoiditis, which is a condition where one of the membranes surrounding the spinal cord swells, implantable infusion pumps deliver lower dosages of drugs and tend to provide more efficient pain relief. The prevalence of chronic diseases is expected to increase by 57% by 2020, according to the World Health Organization. Therefore, the rise in the prevalence of chronic diseases is expected to drive the growth of the implantable infusion pumps market. The safety concern regarding implantable infusion pumps is a key factor hampering the growth of the implantable infusion pumps market. The magnetic resonance (MR) system can be useful in the diagnosis of a wide range of conditions and diseases, but the MRI setting poses a risk factor for patients with implantable infusion pumps. An MRI examination can influence the programming or functionality of an infusion pump, even if specific requirements have been met. The US food and drug administration received evidence of significant adverse effects including harm to the patient and death associated with the use of implantable infusion pumps in the MR field. Therefore, the safety concerns regarding implantable infusion pumps are expected to limit the growth of the implantable infusion pumps market. Companies in the implantable infusion pump market are increasingly focusing on developing smart infusion pumps. The use of wireless technology in health monitoring devices is increasing, which enhances the ease of usage, connectivity, and data analysis. The integration of wireless technology allows the transfer of data from the device to a smartphone or a wireless device through Bluetooth or cellular connection for data processing and then to display the results, which can be used for further study and to check the health condition of the individual. Software platforms are being developed that allow patient monitoring and reduce human error. In June 2019, Ivenix, a US-based medical device company, received clearance for a new smart infusion pump, which reduces human and software error with more streamlined technology. In September 2019, Baxter International Inc., a global medical products company, acquired Cheetah Medical for $190 million. This deal is expected to expand Baxter's product portfolio and strengthen the company's clinical outcomes with patient monitoring technology. Cheetah Medical is a US-based device company offering non-invasive cardiac output and hemodynamic monitoring devices including infusion pumps. Major players in the implantable infusion pumps market are Medtronic, Boston Scientific Corporation, Nevro Corporation, Cyberonics, Baxter, B. Braun Melsungen AG, Fresenius Kabi AG, Smiths Medical, Terumo Corporation, and Neuropace. North America was the largest region in the implantable infusion pumps market in 2021. Asia Pacific was the second-largest region in the global implantable infusion pump market. The regions covered in the global implantable infusion pumps market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the implantable infusion pumps market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global implantable infusion pumps market is segmented - 1) By Type: Patient-Controlled Analgesia (PCA) Pumps, Enteral Pumps, Insulin Pumps, Elastomeric Pumps, Syringe Pumps, Others 2) By Application: Oncology, Pediatrics/Neonatology, Gastroenterology, Hematology, Diabetes, Others 3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics

The injectable drug delivery devices market consists of sales of conventional syringes, needle-free injectors, auto-injectors, and pen injectors. These are used for various routes of drug administration, such as intravenous, subcutaneous, intradermal, intraperitoneal, and intramuscular, and others to treat medical conditions ranging from cancer to autoimmune disorders. The main types of injectable drug delivery devices are conventional injectable, pre-filled syringes, auto-injectors, and pen-injectors. The prefilled syringes are the packaging with the fixed needle that contains single-dose vaccines or other medications. The injectable drug delivery devices offer applications such as autoimmune diseases, hormonal disorders, oncology, orphan diseases, pain management, respiratory therapy, and others that are used by various end-users such as hospitals and clinics, home healthcare settings, pharmaceutical and biotechnological companies, research laboratories, and others. The global injectable drug delivery devices market size is expected to grow from $34.49 billion in 2021 to $38.03 billion in 2022 at a compound annual growth rate (CAGR) of 10.3%. The global injectable drug delivery market size is then expected to grow to $55.89 billion in 2026 at a CAGR of 10.1%. The increasing preference for self-injection devices is driving the injectable drug delivery devices market. Self-injection devices are medical devices that can be used by the patient in-home setting for self-administration of the medication. Self-injection devices include needle-free, auto, pen, and wearable injectors. These self-injectables were developed to provide the most adaptable device which has a high precision of drug delivery and is easy to use. In addition, with the innovations in self-injectable devices, the acceptance of these products has increased over the past few years. BD Physioject is a disposable auto-injector, manufactured by Becton, Dickinson, and Company, which is clinically proven, reliable, and cost-effective specifically designed for self-injection of drugs by patients suffering from chronic diseases, including rheumatoid arthritis, multiple sclerosis, asthma, and osteoporosis. The other companies currently involved in the self-injections market include Abbvie, Inc., 3M, Baxter, Gerresheimer AG, Pfizer Inc, and more. The advantages of self-injectable injections and increasing awareness of self-administration have increased the demand for self-injectable devices and will drive the injectable drug delivery devices market during the forecast period. The emergence of alternative drug delivery devices to injectable drug delivery devices is negatively affecting the market. Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery systems. There are many alternative (painless) drug delivery systems such as nasal, transdermal, transmucosal, vaginal, anal, and others that are evolving. The selection of a drug delivery system depends on the drug release, absorption, distribution, metabolism, and elimination profile of the therapeutic agent to achieve the highest level of safety and efficacy from the drug. Alternative drug delivery systems hold key importance in improving bioavailability, reducing toxicity, and safety elimination of drug which is administered to treat a particular disease. Growing disease-related complications, regular developments in drugs, and combinations of therapeutic agents are used to treat disease driving the need for alternative drug delivery systems. There are some recent ongoing developments in the field of alternative drug delivery systems mainly in a nanoparticles-based delivery system, intracellular delivery system, neural delivery system, and many more. Thus, the emergence of alternative drug delivery methods limits the growth of the injectable drug delivery devices market. The companies in injectable drug delivery devices are increasingly focusing on the manufacturing of auto-injectors. The auto-injectors are fully automated, highly customized, and reusable injectors that can be used by a patient to perform hundreds of injections. Patients can control the speed of dose delivery to help minimize pain or discomfort during injection. These devices can adjust the speed and depth of the automatic injection. For instance, LISA, a reusable auto-injector manufactured by Unilife corporation comes with an array of highly customizable features including Bluetooth LE connectivity, Wi-Fi or 3G connectivity, and pre-injection drug warming for target therapies. The injectable drug delivery technology market is expected to show significant growth in the coming years, due to various technological advancements and new product launches to improve the convenience and ease of administration of parenteral therapeutics. Major players in the injectable drug delivery devices market are Becton, Dickinson and Company, Gerresheimer AG, Eli Lilly and Company, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Schott AG, Baxter International, Owen Mumford, Mylan N.V., and Sanofi. North America was the largest region in the injectable drug delivery devices market in 2021. Western Europe was the second-largest region in the global injectable drug delivery market. The regions in the global injectable drug delivery device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries included in the injectable drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global injectable drug delivery devices market is segmented - 1) By Type: Conventional Injectable, Prefilled Syringes, Auto-Injectors, Pen-Injectors 2) By Application: Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therapy, Others 3) By End-User: Hospitals and Clinics, Home Healthcare Settings, Pharmaceutical and Biotechnological Companies, Research Laboratories, Others

The nasal splints market consists of sales of nasal splints. These nasal splints are devices that are used to prevent nasal bone movement from their positions to avoid side effects such as nose bleeding, inflammation inside the nostrils, and maintain the shape of the nose after any reconstructive surgery or rhinoplasty. The main types of nasal splints market are malleable nasal splints, airway nasal splints, and bivalve nasal splints. The bivalve nasal splints are designed to provide septal support and reduce or prevent adhesions between the septum and lateral nasal wall following surgery. The various applications involved are plastic surgery, rhinological operations, ENT surgery, and others. The various end-users are hospitals and clinics, home care, research centers, and others. The global nasal splints market size is expected to grow from $4.63 billion in 2021 to $4.99 billion in 2022 at a compound annual growth rate (CAGR) of 7.7%. The global nasal splint market size is expected to grow to $6.48 billion in 2026 at a CAGR of 6.8%. Rhinoplasty is one of the most commonly performed reconstructive cosmetic surgery across the globe and around 207,284 rhinoplasty cosmetic surgeries were performed throughout the world in 2019. As part of the post-operative procedure, intranasal splints are used to promote hemostasis, structural support and minimize scar formation. Therefore, owing to the rising numbers of rhinoplasty surgery and the use of nasal splints for post-operative care, the market for nasal splints is forecasted to grow. The nasal splints market was limited by a shortage of skilled surgeons and other professionals in most developed and developing countries. Equipment fabrication and integration require specialized skillsets relating to nasal surgeries, and electronics and software. According to a survey conducted by the International Society of Aesthetic Plastic Surgery (ISAPS), in the Middle Eastern countries such as Iran, there were only 238 surgeons to perform 37,423 nose jobs. The specialized skillsets relating to nasal surgeries are available to a limited number of organizations, most of which are located in the USA and Europe. This shortage of skilled surgeons and other professionals is a significant deterrent to the growth of the market. Nasal splints made from biodegradable materials are gaining popularity in the industry, as they do not require surgical removal after implantation. The biodegradable materials in nasal splints include plant-based and bioresorbable materials. They help in controlling bleeding after surgery or nasal trauma, eliminating the need for painful nasal packing removal for patients, and act as an adjunct to aid in the natural healing process. For instance, Smith & Nephew offers a dissolvable nasal splint Nasastent composed of plant-based carboxymethyl cellulose that helps to support the soft nasal tissue and provides pressure to prevent bleeding. This implant eventually converts into a hydro colloidal gel after absorbing nasal fluid and drains from the patient naturally. Some of the other companies offering biodegradable nasal splints are Hemostasis LLC, Medtronic and others. As per the US FDA, nasal splints are classified as Class I medical devices that are exempted from premarket notification. However, nasal splint manufacturers must register their establishment and list the generic category or classification name. Major players in the nasal splints market are Boston Medical Products Inc, Innovia Medical LLC, Medtronic plc, Olympus Corporation, Smith & Nephew, DTR Medical, Mentor Worldwide LLC, Network Medical Products, Summit Medical Group, and Surgiform Technologies LLC. Asia Pacific was the largest region in the nasal splints market in 2021. North America was the second-largest region in the global nasal splints market. The regions covered in the global nasal splints market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nasal splints market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The global nasal splints market is segmented - 1) By Type: Malleable Nasal Splints, Airway Nasal Splints, Bivalve Nasal Splints 2) By End-User: Hospitals and Clinics, Homecare, Research Centers, Others 3) By Application: Plastic Surgery, Rhinological Operations, ENT Surgery, Others 4) By Route of Administration: Intranasal Segment, Extranasal Segment

Ambulatory IV Infusion Pumps Market Definition

The ambulatory IV infusion pumps market consists of sales of ambulatory IV infusion pumps and related services by entities (organizations, sole traders, and partnerships) that are used to deliver drugs and other fluids intravenously. Ambulatory infusion pumps are usually plastic handheld devices consisting of a disposable syringe, collapsible bag reservoir, a mechanism for propelling the infusate, a flow- control mechanism, and a means of displaying alarm conditions and/or user prompts. They are used for the controlled delivery of medication into the patient's body. These infusion pumps are suited for delivering fluids in large or small amounts and could be used to deliver nutrients or medications such as insulin or other hormones, antibiotics, chemotherapy drugs, and pain relievers.

The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions. The main therapy types of are oral biologics and biosimilar lymphocyte modulators, interleukin inhibitors and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that stop interleukins from working. Interleukins are a family of cytokines produced by lymphocytes, monocytes, macrophages, and a few other cells. They play an important role in immune system regulation. The various disease treated include asthma, crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others by vaccines, proteins & peptides, monoclonal antibodies and others. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The global oral biologics & biosimilar drugs market size is expected to grow from $4.06 billion in 2021 to $4.91 billion in 2022 at a compound annual growth rate (CAGR) of 21%. The growth in the oral biologics and biosimilar market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The oral biologics and biosimilar drugs market is expected to reach $10.41 billion in 2026 at a CAGR of 20.7%. The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the oral biologics and biosimilar market. Stringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market. The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in 2019 in Australia. Biocon is an Indian based biopharmaceutical company. In 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit. Major players in the oral biologics & biosimilar drugs market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd., Allergan plc, Emisphere Technologies, Enteris BioPharma, Chiasma, Allena Pharmaceuticals, Gelgen, Ganlee, 3sbio, Innovent, Retractable Technologies, Inc., Changchun High Tech, Dong Bao, CP Guojian, GlaxoSmithKline Plc., Concord Biotech, Aurobindo Pharma Ltd., H. Lundbeck A/S, Sanofi-Aventis and Roche. North America was the largest region in the oral biologics and biosimilar drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global oral biologics & biosimilar drugs market is segmented - 1) By Therapy: Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors 2) By Disease: Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others 3) By Molecule Type: Vaccines, Proteins & Peptides, Monoclonal Antibodies, Others 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The oral contraceptive pills market consists of sales of oral contraceptive pills by entities (organizations, sole traders, and partnerships) that are engaged in manufacturing oral contraceptive pills. An oral contraceptive pill is a pill used to discourage pregnancy. It comprises hormones that prevent the emergence of eggs from the ovaries. Most oral contraceptives involve estrogen and progestin. The main types of oral contraceptive pills are combination, progestin only, others. Oral contraceptive pills that contain both estrogen and progestin are known as combination oral contraceptives. Combination birth control pills prevent the ovaries from releasing an egg while also causing changes in the cervical mucus and uterine lining (endometrium) to prevent sperm from joining the egg. The various category of drugs include generic and branded that are distributed by hospital pharmacy, retail pharmacy, clinics, online channel, public channel and NGO, others. The global oral contraceptive pills market size is expected to grow from $18.44 billion in 2021 to $20.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The growth in the oral contraceptive pills market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global oral contraceptive pills market is expected to reach $31.92 billion in 2026 at a CAGR of 12.2%. The high incidence of unintended pregnancies is expected to drive the growth of the oral contraceptive pills market over the coming years. Unintended pregnancy is a pregnancy that is always unwanted, such as a pregnancy where no children have been planned. The University of California, San Francisco (UCSF) study shows that the rates of unwanted pregnancy and abortion declined substantially when women received a one-year prescription of oral contraceptives. According to the World Health Organization (WHO), 74 million women living in low middle-income economies register unplanned pregnancies every year globally. The WHO’s research noticed 4,794 women had an unplanned pregnancy after they had discontinued using contraceptives. Therefore, the need to avoid unintended pregnancies drives the growth of the oral contraceptive pills market. The side effects associated with the use of contraceptive drugs are expected to hinder the growth of the oral contraceptive pills market over the forecast period. An oral contraceptive pill is a hormonal procedure to avoid childbirth. The side effects vary between people and the type of pill consumed. Breast tenderness, headaches, spotting, and nausea are some prominent side effects of oral contraceptive pills. Depo-Provera, an implantable contraceptive, is known to provide the most severe side effects. Research has indicated that Depo-Provera and Depo-SubQ Provera 104 can trigger bone mineral density loss. The U.S. Food and Drug Administration (FDA) attached strict notices to the injection kit saying Depo-Provera and Depo-SubQ Provera 104 could not be used for more than 2 years, attributing to their side effects. The notice also suggests that the use of these medications may increase the risk of osteoporosis and bone disorders later in life. Hence, the side effects associated with the use of contraceptive drugs hamper the growth of the oral contraceptive pill market. Major institutes and companies operating in the oral contraceptive pills sector are focusing on developing innovative solutions for oral contraceptive pills. For instance, in December 2019, a group of scientists from the Massachusetts Institute of Technology (MIT) has created a birth control pill that should only be consumed once a month. The star-shaped capsule may significantly minimize accidental pregnancies caused by users who fail to take their regular dose of the pill. The capsule is filled with gelatin which may stay in the abdomen for weeks after swallowing, from where hormones are slowly released to stop childbirth. In January 2020, Theramex, a specialty pharmaceutical company for women announced the acquisition of rights to Zoely®, a patented oral contraceptive from Merck &Co for an undisclosed amount. This acquisition aids Theramex in global expansion and adding innovative treatment options for women to its portfolio. Merck & Co. is a US-based multinational pharmaceutical company that has oral contraceptives in its product portfolio. Major players in the oral contraceptive pills market are Teva Pharmaceutical Industries Ltd, Bayer AG, Syzygy Healthcare, Mankind Pharma Ltd., Pfizer Inc., Piramal Enterprises Ltd., Ferring B.V, Merck & Co. Inc., Johnson & Johnson and Lupin Pharmaceuticals Inc. The regions covered in the oral contraceptive pills market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oral contraceptive pills market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global oral contraceptive pills market is segmented - 1) By Type: Combination, Progestin Only, Others 2) By Category: Generic, Branded 3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Clinic, Online Channel, Public Channel and NGO, Other